Abstract: New thiazolotriazines having the formula ##STR1## (where R.sup.1 is aryl and R.sup.2 is ar(lower)alkyl, lower alkyl or lower alkenyl) and their pharmaceutically acceptable acid addition salts are described. The corresponding thiazolotriazinium compounds comprising a cation having the formula ##STR2## (where R.sup.1 and R.sup.2 are as explained above and R.sup.3 is ar(lower)alkyl, lower alkyl or lower alkenyl) and a pharmaceutically acceptable anion are also described. The compounds are indicated for use as anti-ulcer agents.

Abstract: The invention concerns novel fused ring indole derivatives of the formula ##STR1## and the pharmaceutically acceptable acid addition and quaternary ammonium salts thereof, wherein n represents 1 or 2 and R.sup.1 represents hydrogen, hydroxyl, lower alkyl, lower alkoxy, trifluoromethyl, halogen, amino or mono- or di-(lower)alkylamino. The compounds are useful as anti-depressant agents.

Abstract: Compounds of formula 1 ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different selected from the group consisting of hydrogen, halogen, nitro, trifluoromethyl, lower alkyl and lower alkoxy, or R.sup.1 and R.sup.2, R.sup.2 and R.sup.3, or R.sup.3 and R.sup.4 together form a CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 chain and R.sup.3 and R.sup.4, R.sup.1 and R.sup.4 and R.sup.1 and R.sup.2, respectively, are as defined above, R.sup.5 is hydrogen, lower alkyl or a radical of formula --Alk--OR.sup.6 wherein Alk is an alkylene selected from the group consisting of CR.sup.7 R.sup.8, CR.sup.7 R.sup.8 CR.sup.9 R.sup.10, CR.sup.7 R.sup.8 CR.sup.9 R.sup.10 CR.sup.11 R.sup.12 and CR.sup.7 R.sup.8 CR.sup.9 R.sup.10 CR.sup.11 R.sup.12 CR.sup.13 R.sup.14 wherein each of R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 is hydrogen or lower alkyl and R.sup.6 is hydrogen or lower alkyl; R.sup.15 is hydrogen or lower alkyl; X is O, S, SO or SO.sub.2 ; Y is O or NR.sup.

Abstract: (Aroylamino)-1-(aroyloxyalkyl)piperidines having the formula ##STR1## WHERE Ar.sup.1 and Ar.sup.2 are aryl (including heteroaryl) groups and n is from 2 to 6, and their pharmaceutically acceptable acid addition salts are described. The piperidine derivatives show hypotensive activity.

Abstract: The invention provides a compound of formula I, ##STR1## wherein R is hydrogen, alkyl of 1-6 carbon atoms, or COR.sup.3 where R.sup.3 is hydrogen, alkyl of 1-5 carbon atoms, alkenyl of 2 to 5 carbon atoms, alkynyl of 2 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms, R.sup.1 is hydrogen or alkyl of 1-6 carbon atoms, R.sup.2 is alkyl of 1-6 carbon atoms and R.sup.3 is as above defined.The compounds are intended for use in the treatment of ulcers or hypersecretion in mammals.

Abstract: This invention relates to compounds having the formula ##STR1## and the pharmaceutically acceptable acid addition and quaternary ammonium salts thereof, wherein R represents phenyl or phenyl substituted by halogen, lower alkyl, hydroxy, trifluoromethyl or lower alkoxy; n represents 0 or 1 and m represents 2 or 3 with the proviso that n plus m equals 3; and R.sup.1 represents phenyl, thienyl, pyridyl, furyl, indolyl or phenyl substituted by halogen, lower alkyl, lower alkoxy, trifluoromethyl or hydroxy, which exhibit antihypertensive activity in warm blooded animals.

Abstract: The invention concerns diarylpyrazole lower alkanoic acids and derivatives which are pharmacologically efficacious as anti-inflammatory agents. The said compounds can be represented by the formula ##STR1## in which one of D, E, F and G represents hydrogen, one is a lower aliphatic acid radical or derivative thereof and the remaining two of D, E, F and G are aryl or heteroaryl radicals.

Abstract: The invention relates to N-acyl thioureas which are derivatives of 1,5-Naphthyridines. The compounds are intermediates for anti-ulcer agents.

Abstract: A new process for preparing 5-oxo-tetrahydroquinolines comprises condensing a compound of formula II with a ##STR1## compound of formula III to obtain a compound of formula I wherein R, R.sup.1, R.sup.2 and R.sup.3 are selected from hydrogen and lower alkyl. Compounds of formula I are intermediates for pharmaceuticals.

Abstract: The invention relates to thioureas which are derivatives of 1,5-Naphthyridines. The compounds are anti-ulcer agents or intermediates therefor.

Abstract: The invention relates to novel cyclopentena[b,e]pyridine derivatives which have a thioamide group in the 7-position. The compounds are anti-ulcer agents.

Abstract: The invention relates to novel pyridine derivatives which have a fused 5,6, or 7-membered saturated hydrocarbon ring adjacent to the nitrogen of the pyridine ring, and a group X situated on said hydrocarbon ring and separated by one carbon atom from the pyridine nitrogen atom, said group X is cyano, CONHR.sup.3, CSNHR.sup.3 or CO.sub.2 R.sup.5 wherein R.sup.3 is selected from hydrogen, lower alkyl and lower aralkyl radicals and R.sup.5 is selected from hydrogen, lower alkyl and lower aralkyl radicals which may be substituted by alkyl, alkoxy, halogen, nitro or trifluoromethyl; other substituents may be present. Compounds wherein X is CSNHR.sup.3 are anti-ulcer agents and the other compounds are intermediates therefor.

Abstract: The invention relates to novel silicon derivatives of tetrahydroquinolines, which are intermediates in a process for preparing 5,6,7,8-tetrahydroquinoline-8-carboxamides and thiocarboxamides.

Abstract: The invention relates to novel benzoquinolizines of the general formula (I) ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein R.sup.1 and R.sup.2 which may be the same or different, each represent hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 represents hydrogen, lower alkyl or aryl and R.sup.4 represents --SO.sub.2 R.sup.5 (where R.sup.5 is lower alkyl or aryl, --CONH.sub.2 or --CXNHR.sup.6 (where X is oxygen or sulphur and R.sup.6 is aryl or aryl.CO.--). The compounds have hypotensive activity.

Abstract: The invention relates to pyrimido 1,2-b!isoquinolines of the formula ##STR1## and their pharmaceutically acceptable acid addition salts. In the formula, R.sup.1 and R.sup.2 each represent hydrogen, hydroxyl, lower alkyl, lower alkoxy, trifluoromethyl, halogen, amino or mono- or di-(lower)alkylamino and R.sup.3 and R.sup.4 each represent hydrogen or lower alkyl. The compounds have utility as anti-gastric ulcer agents.

Abstract: A process for preparing tryptophol derivatives comprises reducing a 3-indolylglyoxylic acid ester or acid halide using an alkali metal borohydride in the presence of an alcohol or ether solvent. The tryptophol derivatives prepared are useful as intermediates to pharmacologically active compounds.

Abstract: The invention provides compounds of general formula I ##STR1## and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof, wherein R represents hydrogen or lower alkyl, R.sup.1 represents hydrogen or lower alkyl, R.sup.2 represents hydrogen or lower alkyl, R.sup.3 represents hydrogen, halogen, lower alkoxy, hydroxy, or lower alkyl, R.sup.4 represents hydrogen, lower alkyl, cycloalkyl of 5 to 7 carbon atoms, thienyl, furyl, phenyl; phenyl mono- or disubstituted by halogen, lower alkyl, lower alkoxy, hydroxy or trifluoromethyl; or benzoyl, halobenzoyl, lower alkanoyl, cycloalkanoyl of 6 to 8 carbon atoms, or thienoyl, A represents an alkylene, mono- or diketo- or hydroxy-alkylene radical having from 1 to 5 carbon atoms and X is oxygen or sulphur.The compounds exhibit action on the cardiovascular system particularly hypotensive and/or anti-hypertensive activity.

Abstract: A group of heterocyclic compounds generally exhibiting central nervous system activity (such as depressant and anti-convulsant activities) and, in some cases, cardiovascular and/or anti-inflammatory activity are described. The compounds have the formula ##STR1## where A is an ethyl or propyl group which is monosubstituted by defined substituents or a di(loweralkyl) amino (loweralkoxy) carbonyl group and R is a phenyl group which may be substituted by defined substituents. Pharmaceutical compositions having hypotensive activity or central nervous system activity comprise a non-toxic carrier and an effective amount of such a compound.

Abstract: Compounds of the formula ##STR1## in which W is quinolyl or lower alkyl quinolyl;A is alkylene of 1 to 6 carbon atoms;R is phenyl, halophenyl, lower alkoxy phenyl or lower alkyl phenyl;Or a pharmaceutically acceptable acid addition salt thereof, are hypotensive and bradycardial agents.

Abstract: The invention relates to imidazo[1,2-a]quinolines of formula (I) ##STR1## and their pharmaceutically acceptable acid addition salts. In formula I R.sup.1 and R.sup.2 which may be the same or different each represent hydrogen, lower alkyl, lower alkoxy, trifluoromethyl or halogen, R.sup.3 and R.sup.4 which may be the same or different each represent lower alkyl and R.sup.5 represents hydrogen, lower alkyl, aryl or arylloweralkyl. The compounds possess hypotensive activity.